D1063.01 (Triclosan: Irgasan DP300) to Daphnia magna.  Laboratory
Project ID No. 38656.  Prepared by Analytical Bio-Chemistry
Laboratories, Inc, Columbia, Missouri.  Submitted jointly by Proctor and
Gamble Company and Ciba-Geigy Corp.

43740701.  Wuethrich, V.  1990.  Influence of FAT 80023/Q (Irgasan
DP300) on Reproduction of Daphnia magna.  Project No. 262934.  Prepared
by RCC Umweltchemie AG, Itingen, Switzerland.  Submitted by Ciba-Giegy
AG, Basel, Switzerland.

43969301.  Sword, M.C.  1996.  Static Acute Toxicity of Triclosan to
Rainbow Trout.  Study performed by ABC Laboratories, Inc., Columbia,
Missouri.  Laboratory Report No. 42997.  Sponsored by CIBA Chemical
Division, Greensboro, North Carolina.

44422801.  Staveley, J.P. and T.L. Williams.  1997.  Effects of
Triclosan on the Growth and Reproduction of Aquatic Plants.  Study
performed by Carolina Ecotox, Inc., Durham, North Carolina.  Laboratory
Report ID: 21-02-1.  Sponsored by Ciba-Geigy Corporation, Greensboro,
North Carolina.

Federle, T.W., Kaiser, S.K., and Nuck, B.A. 2002. Fate and Effects of
Triclosan in Activated Sludge.  Environmental Toxicology and
Chemistry/SETAC.  21(7): 1330-7.

Kanda, R., Griffin, P., and James, H.A., et al. 2003. Pharmaceutical and
Personal Care Products in Sewage Treatment Works.  Journal of
Environmental Monitoring.  5(5): 823-30.

Klopin, D.W., Furlong, E.T., Meyer, M.T., et al. 2002. Pharmaceuticals,
Hormones, and Other Organic Wastewater Contaminants in U.S. Streams,
1999-2000: A National Reconnaissance. Environmental Science and
Technology. 36(6): 1202-11.

McAvoy, D.C., Schatowitz, B., Martin, J., et al. 2002. Measurement Of
Triclosan In Wastewater Treatment Systems. Environmental Toxicology and
Chemistry. 21 (7): 1323-9.

Dietary REFERENCES

FDA, 2003, A Guidance For Industry: Preparations of food Contact
Notifications and Food Additive Petitions for Food Contact Substances,
Chemistry Recommendations. Final Guidance, April 2003.   HYPERLINK
"http://www.cfsan.fda.gov"  http://www.cfsan.fda.gov

FDA, 2003.  Sanitizing  Solutions: Chemistry Guidance for Food Additive
Petitions, January 2003.   HYPERLINK "Http://www.cfsan.fda.gov"
Http://www.cfsan.fda.gov

An AD Memo by Tim McMahon  to Jess Rowland, Executive Secretary for
Agency’s HIARC Committee, 1998.

Calculations reported by Bob Quick in an AD   Memo by Bob Quick to Bob
Brennis,

1998.

Environmental Fate REFERENCES

420279-08	Pointurier, R. 1990.  Irgasan® DP 300 – Report on
Hydrolysis as a Function of pH.  Unpublished study performed and
submitted by Ciba-Geigy Ltd., Basel, Switzerland.

430226-08	Spare, W. 1993.  Aqueous Photolysis of Triclosan.  Agrisearch
Project No.: 12208.  Unpublished study performed by Agrisearch Inc.,
Frederick, MD; and submitted by Ciba-Geigy Corporation, Greensboro, NC.

--------------	The Estimation Programs Interface (EPI) Suite.  Windows
based suite of physical/chemical properties and environmental estimation
models developed by the US EPA’s Office of Prevention, Pesticides and
Toxic substances (OPPTS) and Syracuse Research Institute (SRC).
Physical properties of Triclosan.  EPI Suite Summary (v3.12).
HYPERLINK "http://www.epa.gov/opptintr/exposure/docs/EPISuitedl.htm"
http://www.epa.gov/opptintr/exposure/docs/EPISuitedl.htm

-------------	Hazard Substances Data Bank (HSDB).  A Database of the
National Library of Medicine’s TOXNET System.  Triclosan:
Environmental Fate and Exposure.  HYPERLINK
"Triclosan%20Fate%20Chapter%20for%20RED.updated%2012-21-06.doc"
http://toxnet.nlm.nih.gov

Agüera, A., Fernandez-Alba, A.R., Luis, P., et al. 2003. Evaluation Of
Triclosan And Biphenylol In Marine Sediments And Urban Wastewaters By
Pressurized Liquid Extraction And Solid Phase Extraction Followed By Gas
Chromatography Mass Spectrometry And Liquid Chromatography Mass
Spectrometry. Analytica Chimica Acta 480: 193-205.

Anderson, P.D., D'Aco, V.J., Shanahan, P., et al. 2004. Screening
Analysis of Human Pharmaceutical Compounds in U.S. Surface Waters.
Environmental Science and Technology. 38(3): 838-49.

Bendz, D., Paxeus, N.A., Ginn, .R., et al. 2005. Occurrence And Fate Of
Pharmaceutically  Active Compounds In The Environment, A Case Study:
Hoje River In Sweden.  Journal of  Hazardous Materials. 122: 195-204.

Bester, K. 2003. Triclosan In A Sewage Treatment Process--Balances And
Monitoring Data. Water Research. 37 (16): 3891-6.

Bester, K. 2005.  Fate of Triclosan and Triclosan-Methyl in Sewage
Treatment Plants and Surface Waters. Archives of Environmental
Contamination and Toxicology. 49 (1): 9-17.

Boyd, G.R., Palmeri, J.M., Zhang, S., et al. 2004. Pharmaceuticals And
Personal Care  Products (PPCPs) And Endocrine Disrupting Chemicals
(EDCs) In Stormwater Canals And Bayou St. John In New Orleans,
Louisiana, USA. Science of the Total Environment. 333 : 137-48.

Boyd, G.R., Reemtsma, H., Grimm, D.A., et al. 2003. Pharmaceuticals And
Personal Care Products (PPCPs) In Surface And Treated Waters Of
Louisiana, USA And Ontario, Canada. Science of the Total Environment
(Netherlands). 311 (1-3): 135-49.

Federle, T.W., Kaiser, S.K., and Nuck, B.A. 2002. Fate and Effects of
Triclosan in Activated Sludge.  Environmental Toxicology and
Chemistry/SETAC.  21(7): 1330-7.

Federle, T.W. and E.L. Schwab. 2003. Triclosan Biodegradation in
Wastewater Treatment Plant Effluent Diluted in Various River Wastes.
Abstr. Gen. Meet Am Soc. Microbiol 103. p. 0-017.

Gatidou, G., Thomaidis, N.S., Stasinakis, A.S., et al. 2007.
Simultaneous Determination Of The Endocrine Disrupting Compounds
Nonylphenol, Nonylphenol Ethoxylates, Triclosan And Bisphenol A In
Wastewater And Sewage Sludge By Gas Chromatography-Mass Spectrometry.
Journal of Chromatography A. 1138: 32-41.

Gomez, M.J., Martinez Bueno, M.J., Lacorte, S., et al. 2007. Pilot
Survey Monitoring Pharmaceuticals And Related Compounds In A Sewage
Treatment Plant Located On The Mediterranean Coast. Chemosphere. 66 (6):
993-1002.

Hua, W., Bennett, E.R., Letcher, R.J. 2005. Triclosan In Waste And
Surface Waters From The Upper Detroit River By Liquid
Chromatography-Electrospray-Tandem Quadrupole Mass Spectrometry.
Environment International. 31: 621-30.

Kanda, R., Griffin, P., and James, H.A., et al. 2003. Pharmaceutical and
Personal Care Products in Sewage Treatment Works.  Journal of
Environmental Monitoring.  5(5): 823-30.

Kolpin, D.W., Furlong, E.T., Meyer, M.T., et al. 2002. Pharmaceuticals,
Hormones, and Other Organic Wastewater Contaminants in U.S. Streams,
1999-2000: A National Reconnaissance. Environmental Science and
Technology. 36(6): 1202-11.

Lee, H., and Peart, T.E. 2002. Organic Contaminants in Canadian
Municipal Sewage Sludge. Part I. Toxic or Endocrine-disrupting Phenolic
Compounds. Water Quality Research Journal of Canada. 37(4): 681-696.

Lee, H., Sarafin, K., and Peart, T.E., et al. 2003. Acidic
Pharmaceuticals in Sewage: Methodology, Stability Test, Occurrence, and
Removal from Ontario Samples. Water Quality Research Journal of Canada.
38(4): 667-682.

Lee, H., Peart, T.E., and Svoboda, M.L. 2005. Determination of
Endocrine-Disrupting Phenols, Acidic Pharmaceuticals, and Personal-care
Products in Sewage by Solid-phase Extraction and Gas Chromatography-Mass
Spectrometry. Journal of Chromatography. 1094(1-2): 122-9.

Lindstrom, A., Buerge, I.J., Poiger, T., et al. 2002. Occurrence and
environmental behavior of the bactericide triclosan and its methyl
derivative in surface waters and in wastewater. Environmental Science
Technology. 36: 2322-2329. Comment in Environmental Science
Technolology. 36 (11): 228A-230A.

Loraine, G.A., Pettigrove, M.E. 2006. Seasonal Variations In
Concentrations Of Pharmaceuticals And Personal Care Products In Drinking
Water And Reclaimed Wastewater In Southern California. Environmental
Science and Technology. 40(3): 687-95.

McAvoy, D.C., Schatowitz, B., Martin, J., et al. 2002. Measurement Of
Triclosan In Wastewater Treatment Systems. Environmental Toxicology and
Chemistry. 21 (7): 1323-9.

Mezcua, M., Gomez, M.J., Ferrer, I., et al. 2004. Evidence of
2,7/2,8-Dibenzodichloro-p-dioxin As A Photodegradation Product Of
Triclosan In Water And Wastewater Samples. Analytica Chimica Acta. 524
(1-2): 241-247.

Morales, S., Canosa, P., and Rodriguez, I., et al. 2005. Microwave
Assisted Extraction Followed by Gas Chromatography with Tandem Mass
Spectrometry for the Determination of Triclosan and Two Related
Chlorophenols in Sludge and Sediments. Journal of Chromatography. 1082:
128-35.

Nakada, N., Toshikatsu, T., and Hiroyuki, S., et al. 2006.
Pharmaceutical Chemicals and Endocrine Disrupters in Municipal
Wastewater in Tokyo and their Removal during Activated Sludge Treatment.
Water Research. 40(17): 3297-303.

Paxeus, N., and Gryaab, K. 2004. Removal Of Selected Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs), Gemfibrozil, Carbamazepine,
Beta-Blockers, Trimethoprim And Triclosan In Conventional Wastewater
Treatment Plants In Five EU Countries And Their Discharge To The Aquatic
Environment. Water Science and Technology. 50 (5): 253-60.

Sabaliunas, D., Webb, S.F., Hauk, A., et al. 2003. Environmental Fate Of
Triclosan In The River Aire Basin, UK. Water Research (England). 37:
3145-54.

Samsoe-Petersen L.,Winther-Nielsen M., Madsen T. Fate and Effects of
Triclosan.

Environment Project No. 861. Copenhagen: Danish Environmental Protection

Agency; 2003.

Shiraishi, H., Otsuki, A., and Fuwa, K. 1985. Identification Of
Extractable Organic Chemicals In Sewage Effluent By Gas
Chromatography/Mass Spectrometry. Biomedical Mass Spectrometry. 12 (2):
86-94.

Singer, H., Muller, S., Tixier, C., et al. 2002. Triclosan: Occurrence
And Fate Of A Widely Used Biocide In The Aquatic Environment: Field
Measurements In Wastewater Treatment Plants, Surface Waters, And Lake
Sediments. Environmental Science and Technology. 36(23): 4998-5004.

Thomas, P.M., and Foster, G.D. 2004. Determination of Nonsteroidal
Anti-inflammatory Drugs, Caffeine, and Triclosan in Wastewater by Gas
Chromatography-Mass Spectrometry.2004. Journal of Environmental Science
and Health.  Part A, Toxic/Hazardous Substances & Environmental
Engineering. 39(8): 1969-78.

Thomas, P.M., and Foster, G.D. 2005. Tracking Acidic Pharmaceuticals,
Caffeine, And Triclosan Through The Wastewater Treatment Process.
Environmental Toxicology and Chemistry. 24 (1): 25-30.

Thompson, A., Griffin, P., and Stuetz, R., et al. 2005. The Fate and
Removal of Triclosan during Wastewater Treatment.  Water Environment
Research. 77(1):63-67.

Waltman, E.L., Venables, B.J., and Waller, W.T. 2006. Triclosan In A
North Texas Wastewater Treatment Plant And The Influent And Effluent Of
An Experimental Constructed Wetland. Environmental Toxicology and
Chemistry. 25 (2): 367-72.

Wind, T., Werner, U., Jacob, M., et al. 2004. Environmental
Concentrations Of Boron,  LAS, EDTA, NTA and Triclosan Simulated with
GREAT-ER in the river Itter. Chemosphere (England). 54: 1135-44.

Ying, G. and Kookana, R.S. 2007. Triclosan In Wastewaters And Biosolids
From Australian Wastewater Treatment Plants. Environmental
International. 33 (2): 199-205.

Toxicology REFERENCES

MRID 34335:  Stierlin, H. (1968) “Percutaneous Absorption of GP 41 353
in the Rat and the Rabbit.” (Unpublished study; prepared by J.R.
Geigy, AG, submitted by Ciba-Geigy Corp., Greens- boro, N.C.;
CDL:000506-M)

MRID 43429:  Stenger, E.G.; Scharer, (1963) “Local Effects on Rabbit's
Eye.” (Unpublished study; prepared by J.R. Geigy, AG, Switzerland,
submitted by Ciba-Geigy Corp., Greensboro, N.C.; CDL:108210-J)

MRID 96102:  Burther, B.R.; Gordon, D.E. (1973) “Report to Ciba-Geigy
Corporation: 90-day Subacute Oral Toxicity Study with Irgasan DP-300 in
Beagle Dogs: IBT No. C1435.” (Unpublished study; prepared by
Industrial Bio-Test Laboratories, Inc., submitted by Ciba-Geigy Corp.,
Greensboro, N.C.; CDL:008400-C)

MRID 100178/130187:  Schoenig, G. (1967) “Report to Geigy Chemical
Company: Acute Dermal Toxicity Study on CH 3565: IBT No. A5460.”
(Unpublished study; prepared by Industrial Bio-Test Laboratories, Inc.,
submitted by Ciba-Geigy Corp., Greensboro, N.C.; CDL:000503-D)

MRID 133545:  Goldsmith, L. (1983) 90-Day Oral Toxicity Study in Rats
with Fat 80’023/H: LBI Project No. 22188. Final Report.  (Unpublished
study received Dec. 23, 1983 under 100-502; submitted by Ciba-Geigy
Corp.)

MRID 251773:  Drake, J.C. & Buxtorf, A. (1976) 1 Year Oral Toxicity
Study in Baboons with Compound FAT 80 023/A.  Geigy Pharmaceuticals,
Toxicology Department.

MRID 40623701:  Morseth, S.L. (1988) “Two-Generation Reproduction
Study in Rats with FAT 80’02390” Hazleton Laboratories America, Inc.

MRID 42027906:  Study 1 - Yau, E.T. and Green, J.D. (1986) Fat 80’023
2 Year Oral Administration to Rats; Study 2 – Parkes, D.G. (1986)
Determination of Fat 80’023 in Blood and Tissue Samples Taken During a
Two-Year Chronic Oral Toxicity/Oncogenicity Study in Albino Rats
(24-month Final Report).  Ciba-Geigy Corporation.

MRID 42306902, 43310501: Duchosal F. and Ph. Thevenaz (1990) “4-Hour
Acute Inhalation Toxicity Study with FAT 80’023/Q in Rats”
Ciba-Geigy Ltd.

MRID 42306903: Sachsse, K.; Ullman, L. (1975) Skin Irritation in the
Rabbits after Single Application of FAT 80’023/A.  Unpublished Study
Conducted by Ciba Geigy Ltd., Basel Switzerland.  Project No. Siss 4719.
 Submitted to EPA by Chemical Division of Ciba Geigy Corp.  (9/11/75).

MRID 43022605:  Trutter, Janet A.  (1993)  “13-Week Subchronic Oral
Toxicity Study of Triclosan in CD-1® Mice.”  Hazleton Washington,
Inc.

MRID 43206501:  Wnorowski, Gary.  (1994) “Acute Toxicity Limit Test
for Triclosan (Irgasan® DP 300) Product Safety Labs.

MRID 43206502: Wnorowski, G. (1994) Dermal Sensitization Test-Buehler
Method for Triclosan (Irgasan® DP 300) Lot No. 5.2.0211.0.  Product
Safety Labs; Study No. 2635.  Submitted to EPA by Ciba-Geigy Corp.
Unpublished.

MRID 43328001: Trimmer, Gary W.  (1994) “90-Day Subchronic Dermal
Toxicity Study in the Rat with Satellite Group with Irgasan DP300
(MRD-92-399)” Exxon Biomedical Sciences, Inc.

MRID 43533301: Jones, E., Wilson, L.A. (1988) “Ames Metabolic
Activation Test to Address the Potential Mutagenic Effect of Triclosan
(Irgasan DP 300)” Huntingdon Research Center, Ltd. Cambridgeshire,
England.

MRID 43740801: Heidemann, A. (1990) “Chromosome Aberration Assay in
Chinese Hamster V79 Cells In Vitro with FAT 80’023/Q (Irgasan® DP
300); Cytotest Cell Research GMBH & Co. KG, Federal Republic of Germany;
Study No. 179100.  Unpublished.

MRID 43740802: Volkner, W. (1991) “Chromosome Aberration Assay in Bone
Marrow Cells of the Rat with FAT 80’023/Q (Irgasan® DP300); Cytotest
Cell Research GMBH & Co. KG, Federal Republic of Germany; Study No.
218305.  Unpublished.

MRID 43817502, 43817503: Denning, H.J., Sliwa, S., and Willson, G.A.
(1992) “Triclosan: Effects on Pregnancy and Post-Natal Development in
Rats: Volume 1, Volume 2 and Appendices 1-17” Unilever Research,
Colworth/ Welwyn Lab.

MRID 43820401, 43022607:  Schroeder, R.E. et al. (1992) “A Segment II
Teratology Study in Rabbits with Irgacare MP” Bio/dynamics Inc.

MRID 44389701:  Eldrige, S. (1993) Cell Proliferation in Rodent Liver:
(Triclosan): Final Report: Lab Project Number: 142. Unpublished study
prepared by Pathology Associates, Inc. 14 p.

MRID 44389702:  Molitor, E., Persohn, E., Thomas, H. “The Effect of
FAT 80’023/Q (Irgasan DP 300) on Selected Biochemical Liver Parameters
Following Subchronic Dietary Administration to Male and Female Mice.
Ciba-Geigy Limited, Switzerland, Report CB 91/18, May 22, 1992.

MRID 44389703:  Molitor, E.; Persohn, E. (1993) The Effects of FAT
80’023/Q (Irgasan DP 300) on Selected Biochemical and Morphological
Liver Parameters Following Dietary Administration to Male Rats: Lab
Project Number: CB 92/28.  Unpublished study prepared by Ciba-Geigy Ltd.
70p.

MRID 44389704: Henderson, L.M., et al.  (1988) An Assessment of the
Mutagenic Potential of Triclosan Using the Mouse Lymphoma TK Locus
Assay.  Huntingdon Research Center Ltd., Huntingdon, Cambridgeshire,
PE18 6ES, England. Study No. ULR 216/88644. Unpublished.

MRID 44389705: Stankowski, L.F., Jr. et al. (1993) Amended Final Report,
Ames/Salmonella Plate Incorporation Assay on Test Article 39316 (CC
#14663-09).  Pharmakon USA, P.O. Box 609, Waverly, PA.  Laboratory Study
Report No. PH 301-CP-001-93.  Unpublished.

MRID 44389706: Thomas, Rer. Nat. H. (1994) The Effect of FAT 80’023/Q
and the Model Inducers Phenobarbitone, 3-Methylcholanthrene,
Pregnenolone 16 ∞ -carbonitrile and Nafenopin on Selected Biochemical
and Morphological Liver Parameters in the Syrian Hamster.  Study
conducted by Ciba-Geigy Limited.  Study number CB 93/40.  Unpublished.

MRID 44389707: Thevenaz, Dr. Phil.  (1987) Final Report: FAT 80023:
28-Day Toxicity Study in Mice (Administration in Feed) with Special
Reference to Histopathology.  Ciba-Geigy Ltd., Basle, Switzerland.
Unpublished.

MRID 44389708: Burns, J.M. (1997) 14-Day Repeated Dose Dermal Study of
Triclosan in CD-1 Mice.  Corning Hazleton Incorporated (CHV), 9200
Leesburg Pike, Vienna, Virginia.  Laboratory Study No. CHV 2763-100.
April 29, 1997.  Unpublished.

MRID 44389710: Burns, J.M. (1997) 14-Day Repeated Dose Dermal Study of
Triclosan in Rats.  Corning Hazleton Incorporated (CHV), 9200 Leesburg
Pike, Vienna, Virginia.  Laboratory Study No. CHV 6718-102.
Unpublished.

MRID 44874001, 44751101: Chambers, P.R. (1999) “Potential Tumorigenic
and Chronic Toxicity Effects in Prolonged Dietary Administration to
Hamsters.”  Huntingdon Life Sciences Ltd., Huntingdon, England. CBG
756/972896.

MRID 45307501, 45307502:  Van Dijk, Dr. A. (1994) “14C- Triclosan:
Absorption, Distribution, Metabolism, and Elimination after
Single/Repeated Oral and Intravenous Administration to Hamsters.”  RCC
Umweltchemie AG.  RCC Project No. 351707.

MRID 45307503:  Van Dijk, Dr. A. (1995) “14C- Triclosan: Absorption,
Distribution, Metabolism, and Elimination after Single/Repeated Oral and
Intravenous Administration to Mice.”  RCC Umweltchemie AG.  RCC
Project No. 337781.

Tox Record No. 001955, 001956 (1968)

Tox Record No. 001968 (1977)

Allmyr, M.; McLachlan, MS; Sandborgh-Englund, G.; and Adolfsson-Erici,
M. 2006. Determination of Triclosan as Its Pentafluorobenzoyl Ester in
Human Plasma and Milk Using Electron Capture Negative Ionization Mass
Spectrometry.  Anal. Chem. 2006, 78, 6542-6546.

Capen, C. Toxic Responses of the Endocrine System. In: Casarett and
Doull’s Toxicology: The Basic Science of Poisons, 5th ed., Curtis D.
Klaassen, Ph.D., editor. McGraw-Hill.

Crofton, KM; Paul, KB; DeVito, PB; Hedgea, JH.  2007.  Short-term in
vivo exposure to the water contaminant triclosan: Evidence for
disruption of thyroxine.  Environmental Toxicology and Pharmacology 24:
194–197.

Flaherty, C.M. and S.I. Dodson. (2005). Effects of pharmaceuticals on
Daphnia survival, growth, reproduction. MRID to be assigned.
Chemosphere. 61: 200-207.

Hanioka, N. et. al. (1996) effect of
2,4,4’-Trichloro-2’-hydroxyphenyl Ether on Cytochrome P450 Enzymes
in the Rat Liver. MRID to be added. Chemosphere. 34: 719-730.

Hovander, L. et. al. (2001). Identification of Hydroxylation PCB
Metabolites and Other Phenolic Halogenated Pollutants in Human Blood
Plasma. MRID to be added. Environmental Contamination and Toxicology.
42: 105-117.

Ishibashi, H.; Matsumura, N.; Hirano, M.; Matsuoka, M.; Shiratsuchi, H.;
Ishibashi, Y.; Takao, Y.; and Arizono, K. 2004. Effects of triclosan on
the early life stages and reproduction of medaka Oryzias latipes and
induction of hepatic vitellogenin. Aquatic Toxicology 67:167–179

Matsumura, N.; Ishibashi, H.; Hirano, M.; Nagao, Watanabe N;
Shiratsuchi, H; Kai, T;  Nishimura, T.; Kashiwagi,  A.. and Arizono,  K.
2005. Effects of nonylphenol and triclosan on production of plasma
vitellogenin and testosterone in male South African clawed frogs
(Xenopus laevis).Biol. Pharm. Bull. 28: 1748–1751.

Palenske, N.M., Dzialowski, E.M (2005). Effects of the Environmental
Contaminant Triclosan on the Physiology of Developing Xenopus Laevis
Tadpoles. Integrative and Comparative Biology. 45(6): 1175. Published.

Tamura,H., Y. Ishimoto., T. Fujikawa et al. (2006). Use of Structural
basis for androgen receptor agonists and  Antagonists: Interaction of
SPEED 98-listed chemicals and  Related compounds with the androgen
receptor based on an In vitro reporter gene assay and 3D-QSAR. MRID to
be Assigned. Bioorganic & Medicinal Chemistry. 14:7160-7174.

Veldhoen, N; Skirrow, RC; Osachoff, H.; Wigmore, H; Clapson, DJ;
Gunderson, MP; Aggelen, GV; Helbing, CC. (2006).  The bactericidal agent
triclosan modulates thyroid hormone-associated gene expression and
disrupts postembryonic anuran development.  Aquatic Toxicology 80:
217–227.

U.S. EPA 2008). T. E. Stoker and W. Setzer. The Endocrine Disrupting
Effects of Triclosan, a common pharmaceutical and personal care product:
Alteration of the Thyroid Axis Following a Peri-juvenile Exposure in the
Male Wistar Rat. EPA/600/X-08/010.

Broker, P.C., Gray, V.M., Howell, A.  (1988)  “Analysis of Metaphase
Chromosomes Obtained from CHO Cells Cultured in vitro and Treated with
Triclosan.” Huntingdon Research Center, Ltd. ULR 214/88731; Unilever
Test #: KC880171. Unpublished.

Eldrige, S. (1995) Cell Proliferation in Rodent Liver.  Study conducted
by Pathology Associates, Inc. Submitted to EPA (no MRID). Unpublished.

San Sebastian, J.R., Morgan, J.M. (1993) “Rat Hepatocyte Primary
Culture/DNA Repair Test on 39317” Pharmakon Research International,
Inc. Pharmakon Study #: PH311-CP-001-93.  Unpublished.

See, Norman A.  (1996) Review and Evaluation of Pharmacology and
Toxicology Data Division of Dermatologic and Dental Drug Products
(HFD-540) Food and Drug Administration.

Human Exposure REFERENCES

Calafat AM, Ye X, Wong LY, Reidy JA, and Needham LL.  2007.  Urinary
Concentrations of Triclosan in the U.S. Population:  2003-2004.
Environmental Health Perspectives.  Dated December 7, 2007.  Available
online at   HYPERLINK "http://dx.doi.org"  http://dx.doi.org /

Cauosa (2007).  Determination of Parabens and Triclosan in Indoor Dust
Using Matrix Solid-Phase Dispersion and Gas Chromatography with Tandem
Mass Spectrometry.  Anal. Chem. 2007, 79, 1675-1681.

Cohen J.  2008.  Computations of Human Triclosan Dose Based On NHANES
Urine Concentrations.  Memorandum from Dr. Jonathan Cohen, ICF
International to Tim Leighton, David Miller, Philip Villaneuva, USEPA,
dated March 6, 2008.  Contract EP-W-06-091, WA 0-02, TAF CM 19.

Dayan AD.  2007.  Risk assessment of triclosan [Irgasan] in human breast
milk.  Food and Chemical Toxicology 45 (2007) 125-129.

DOE.  1997.  Energy Information Administration: Profile of Commercial
Buildings in 1995.
http://www.eia.doe.gov/emeu/cbecs/char95/profile.html

  SEQ CHAPTER \h \r 1 Freeman, N , Jimenez M, Reed KJ,Gurunathan S,
Edwards RD, Roy A, Adgate JL, Pellizzari ED, Quackenboss J, Sexton K,
Lioy PJ, 2001.  Quantitative analysis of chilren’s microactivity
patterns:  The Minnesota Children’s Pesticide Exposure Study.  Journal
of Exposure Analysis and Environmental Epidemiology.  11(6): 501-509.

Geigy. 1981. Geigy Scientific Tables, Volume 1. Units of measurement,
body fluids, composition of the body, nutrition. Eighth edition. (Edited
by C. Lentner). CIBA-GEIGY.

Mage D.T., Allen R., Gondy G., Smith W., Barr D.B., Needham L.L. 2004.
Estimating Pesticide Dose from Pesticide Exposure Data by Creatinine
Correction in the Third National Health and Nutrition Examination Survey
(NHANES-III). J Exposure Anal Environ Epidemiol 14:457-465.

Mage D.T., Allen, R.H., Kodali, A. 2007. Creatinine corrections for
estimating children’s and adult’s pesticide intake doses in
equilibrium with urinary pesticide and creatinine concentrations. J
Exposure Sci Environ Epidemiol 1-9.

Sandborgh-Englund G, Adolfsson-Erici M, Odham G, and Ekstrand J.  2006.
Pharmacokinetics of Triclosan Following Oral Ingestion in Humans.
Journal of Toxicology and Environmental Health, Part A, 69:1861-1873,
2006.

Schafer, K.S,, Reeves, M., Spitzer, S., Kegley, S. E. 2004. Chemical
Trespass: Pesticides in Our Bodies and Corporate Accountability.
Pesticide Action Network North America. May 2004.

USEPA. 1996.  Office of Research and Development, Descriptive Statistics
Tables from a Detailed Analysis of the National Human Activity Pattern
(NHAPS) Data; EPA/600/R-96/148, July 1996.   Data Collection Period
October 1992 - September 1994 .

USEPA.  1997.  Exposure Factors Handbook. Volume I-II.  Office of
Research and Development.  Washington, D.C.  EPA/600/P-95/002Fa. August
1997.

USEPA. 1998. PHED Surrogate Exposure Guide. Estimates of Worker Exposure
from the Pesticide Handler Exposure Database Version 1.1.   Washington,
DC:  U.S. Environmental Protection Agency.

  SEQ CHAPTER \h \r 1 USEPA. 1999.  Evaluation of Chemical Manufacturers
Association Antimicrobial Exposure Assessment Study (Amended on 8
December 1992).  Memorandum from Siroos Mostaghimi, PH.D., USEPA to
Julie Fairfax, USEPA. Dated November, 4 1999.  DP Barcode D247642.

hÅ

H

L

`

i

j

Ü

û

ü

2

;

<

H

%

&

Ù

Ú

$

%

&

/

1

z

…

ˆ

Œ

—

˜

¨

¬

·

¸

Ë

Ì

Ø

ì

ü

ý

 hÅ

 hÅ

 hÅ

gd

h

h

 h

 h

h

옍

h

h

Ø	@

옍)

@

옍#

h7

h7

h7

h7

h7

h7

h7

h7

摧㛕Ò᠀

hW

愀Ĥ摧憥4 ̀Ĥ옍

愀Ĥ摧憥4 ̀Ĥ옍

̀Ĥ옍

̀Ĥ옍

̀Ĥ옍

̀Ĥ옍

̀Ĥ옍

̀Ĥ옍

̀Ĥ옍

愀Ĥ摧憥4 ̀Ĥ옍

愀Ĥ摧憥4 ̀Ĥ옍

Ø	@

Æ

Æ

Æ

ఆ

Æ

Æ

Æ

ఆ

Ø	@

Ø	@

Æ

Æ

Æ

Æ

Æ

ఆ

Ø	@

Æ

Æ

ఆ

Ø	@

Æ

Æ

ఆ

Ø	@

Æ

Æ

ఆ

ఆ

¢

;

¡

¢

£

¤

¥

Ø

Ù

@¢

£

¥

¦

§

¨

©

ª

«

¬

×

Ø

Ù

옍)

옍)

 hÕr

'†

'†

'†

'†

'†

'†

'†

'†

옍)

 hÅ

 hÅ

@

@

@

h/

h/

h/

h/

h/

@

h/

h/

h/

h/

h/

h/

h/

h/

h/

h/

h/

옍)

h/

h/

@

{

 hÅ

 hÅ

{

摧㗝é

{

摧㗝é

਀Ħ䘋

摧㗝é

摧㗝é

摧㗝é

摧㗝é

옍

옍

 h¼

옍

옍

਀Ħ䘋

摧⣭t

਀&䘋

S

T

3

4

±

¾

 hÅ

  hÅ

  hÅ

B*OJ

QJ

^J

OJ

QJ

옍)

 hë

icide Programs, Human Health Effects Division. Dated April 5, 2000.

USEPA.  2001.  HED Science Advisory Council for Exposure. Policy Update,
November 12.  Recommended Revisions to the Standard Operating Procedures
(SOPs) for Residential Exposure Assessment, February 22, 2001.

USEPA.  2002. CHILD-SPECIFIC EXPOSURE FACTORS HANDBOOK (INTERIM REPORT).
USEPA EPA-600-P-00-002B. 01 Sep 2002. U.S. Environmental Protection
Agency, Office of Research and Development, National Center for
Environmental Assessment, Washington Office, Washington, DC, 448.

USEPA.  2005.  Guidance on Selecting Age Groups for Monitoring and
Assessing Childhood Exposures to Environmental Contaminants.  Risk
Assessment Forum, U.S. Environmental Protection Agency, November 2005.
EPA/630/P-03/003F.

USEPA.  2007.  5-Chloro-2-(2,4-dichlorophenoxy)phenol (triclosan):
Toxicology Chapter for the Reregistration Eligibility Decision (RED)
document.

Product Chemistry References

42027901	LoMenzo, J. (1991) Irgasan DP 300: Product Identity and
Composition. Unpublished study prepared by Ciba-Geigy Corp.

42027902	Basingthwaite, J. (1983) Irgasan DP 300: Batch Analysis and
Analytical Methodology. Unpublished study prepared by Ciba-Geigy Ag.

42027904	Vogel, A. (1990) Irgasan 300 DP: Report on Melting
Point/Melting Range. Unpublished study prepared by Ciba-Geigy Ltd.

43022601	Morrissey, M. (1993) Stability Determination of Irgasan DP 300
in the Presence of Metal: Final Report: Lab Project Number: HWI
6117-246. Unpublished study prepared by Hazleton Wisconsin, Inc.

43277801	Morrissey, M. (1994) Stability Determination of Irgasan DP300
Exposed to Metal Ions: Final Report: Lab Project Number: HWI 6117-261.
Unpublished study prepared by Hazleton Wisconsin, Inc.

43277802	Schatowitz, B. (1990) Additional Data Required by the US EPA
for the Results of the Analysis of Irgasan DP300 for Dioxins/Furans: Lab
Project Number: 102290. Unpublished study prepared by Ciba-Geigy Ltd.

43533901	Schatowitz, B. (1995) Additional Data Required by the U.S. EPA
for the Product Analysis of Irgasan DP 300: Lab Project Number: 11995.
Unpublished study prepared by Ciba Research Services.

 As discussed in the revised triclosan environmental fate chapter, only
acute concentrations of concern were evaluated for aquatic organisms
since acceptable chronic aquatic data are not available.  However,
considering the low probability of triclosan being released into
household wastewater and surface waters, EPA also concludes that chronic
aquatic risks are unlikely from consumer uses of triclosan-treated
plastic and textile items.

  EPA assumes that leaching values for plastic are of the same magnitude
as for textile products.  Note that the Agency used the 0.55 % leaching
value in its evaluation for children who may mouth (incidental oral
ingestion) plastic items (e.g., toys).

 The Agency is making this statement because triclosan and triclosan
transformation products are being detected in various environmental
components (see triclosan environmental fate chapter).

 PAGE

 PAGE   65


[Federal Register Volume 81, Number 128 (Tuesday, July 5, 2016)]
[Notices]
[Pages 43678-43680]
[FR Doc No: 2016-15761]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-78188; File No. SR-NASDAQ-2016-082]

Self-Regulatory Organizations; The Nasdaq Stock Market LLC;
Notice of Filing and Immediate Effectiveness of Proposed Rule Change
Relating to the Listing and Trading of the Shares of the AdvisorShares
Market Adaptive Unconstrained Income ETF of the AdvisorShares Trust

June 28, 2016.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice is hereby given that
on June 15, 2016, The Nasdaq Stock Market LLC (``Exchange'') filed with
the Securities and Exchange Commission (``SEC'' or ``Commission'') the
proposed rule change as described in Items I, II, and III, below, which
Items have been prepared by the Exchange. The Commission is publishing
this notice to solicit comments on the proposed rule change from
interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    Nasdaq proposes a rule change to the investment objective and the
means of achieving the investment objective with

respect to the AdvisorShares Market Adaptive Unconstrained Income ETF
(the ``Fund''), formerly known as the AdvisorShares Sunrise Global
Multi-Strategy ETF. Shares of the Market Adaptive Unconstrained Income
ETF are currently listed and traded on the Exchange''). The Fund is a
series of AdvisorShares Trust (the ``Trust''), under Nasdaq Rule 5735
(``Managed Fund Shares'').\3\ The shares of the Fund are collectively
referred to herein as the ``Shares.''
---------------------------------------------------------------------------

    \3\ The Commission approved Nasdaq Rule 5735 in Securities
Exchange Act Release No. 57962 (June 13, 2008) 73 FR 35175 (June 20,
2008) (SR-NASDAQ-2008-039). There are already multiple actively-
managed funds listed on the Exchange; see Securities Exchange Act
Release No. 66489 (February 29, 2012), 77 FR 13379 (March 6, 2012)
(SR-NASDAQ-2012-004) (order approving listing and trading of
WisdomTree Emerging Markets Corporate Bond Fund). Additionally, the
Commission has previously approved the listing and trading of a
number of actively-managed WisdomTree funds on NYSE Arca, Inc.
pursuant to Rule 8.600 of that exchange. See, e.g., Securities
Exchange Act Release No. 64643 (June 10, 2011), 76 FR 35062 (June
15, 2011) (SR-NYSEArca-2011-21) (order approving listing and trading
of WisdomTree Global Real Return Fund). The Exchange believes the
proposed rule change raises no significant issues not previously
addressed in those prior Commission orders.
---------------------------------------------------------------------------

    The text of the proposed rule change is available at http://nasdaq.cchwallstreet.com/, at Nasdaq's principal office, and at the
Commission's Public Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, Nasdaq included statements
concerning the purpose of, and basis for, the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. Nasdaq has prepared summaries, set forth in Sections A,
B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The Commission has previously approved the listing and trading on
the Exchange of Shares of the AdvisorShares Market Adaptive
Unconstrained Income ETF (the ``Fund''), formerly known as the
AdvisorShares Sunrise Global Multi-Strategy ETF, a series of
AdvisorShares Trust (the ``Trust''), under Nasdaq Rule 5735 (``Managed
Fund Shares'').\4\ The shares of the Fund are collectively referred to
herein as the ``Shares.'' Shares of the Fund are currently listed and
traded on the Exchange.
---------------------------------------------------------------------------

    \4\ See Securities Exchange Act Release No. 72426 (June 18,
2014), 79 FR 35825 (June 24, 2014) (SR-NASDAQ-2014-035) (order
approving listing and trading of AdvisorShares Sunrise Global Multi-
Strategy ETF, the ``Prior Release'').
---------------------------------------------------------------------------

    The Shares are offered by the Trust, which is registered with the
Commission as an open-end management investment company. The investment
advisor to the Fund is AdvisorShares Investments, LLC (the
``Adviser''). The sub-adviser for the Fund is American Wealth
Management (the ``Sub-Adviser''). The Adviser is not registered as a
broker-dealer or affiliated with a broker-dealer. The Sub-advisor is
registered as a broker dealer, but has implemented a ``fire wall''
between the investment adviser and the broker-dealer.
    Paragraph (g) of Rule 5735 provides that if the investment adviser
to the investment company issuing Managed Fund Shares is affiliated
with a broker-dealer, such investment adviser shall erect a ``fire
wall'' between the investment adviser and the broker-dealer with
respect to access to information concerning the composition and/or
changes to such investment company portfolio.\5\ In addition, paragraph
(g) further requires that personnel who make decisions on the open-end
fund's portfolio composition must be subject to procedures designed to
prevent the use and dissemination of material, non-public information
regarding the open-end fund's portfolio. Rule 5735(g) is similar to
Nasdaq Rule 5705(b)(5)(A)(i); however, paragraph (g) in connection with
the establishment of a ``fire wall'' between the investment adviser and
the broker-dealer reflects the applicable open-end fund's portfolio,
not an underlying benchmark index, as is the case with index-based
funds. In the event (a) the Adviser or the Sub-Adviser becomes newly
affiliated with a broker-dealer or registers as a broker-dealer, or (b)
any new adviser or sub-adviser is a registered broker-dealer or becomes
affiliated with a broker-dealer, it will implement a fire wall with
respect to its relevant personnel and/or such broker-dealer affiliate,
if applicable, regarding access to information concerning the
composition and/or changes to the portfolio and will be subject to
procedures designed to prevent the use and dissemination of material
non-public information regarding such portfolio.
---------------------------------------------------------------------------

    \5\ An investment adviser to an open-end fund is required to be
registered under the Investment Advisers Act of 1940 (the ``Advisers
Act''). As a result, the Adviser and its related personnel are
subject to the provisions of Rule 204A-1 under the Advisers Act
relating to codes of ethics. This rule requires investment advisers
to adopt a code of ethics that reflects the fiduciary nature of the
relationship to clients as well as compliance with other applicable
securities laws. Accordingly, procedures designed to prevent the
communication and misuse of non-public information by an investment
adviser must be consistent with Rule 204A-1 under the Advisers Act.
In addition, Rule 206(4)-7 under the Advisers Act makes it unlawful
for an investment adviser to provide investment advice to clients
unless such investment adviser has (i) adopted and implemented
written policies and procedures reasonably designed to prevent
violation, by the investment adviser and its supervised persons, of
the Advisers Act and the Commission rules adopted thereunder; (ii)
implemented, at a minimum, an annual review regarding the adequacy
of the policies and procedures established pursuant to subparagraph
(i) above and the effectiveness of their implementation; and (iii)
designated an individual (who is a supervised person) responsible
for administering the policies and procedures adopted under
subparagraph (i) above.
---------------------------------------------------------------------------

    Under normal market conditions,\6\ the Fund will seek to achieve
its investment objective by investing at least 80% of its net assets in
the principal investments as discussed below. In this proposed rule
change, the Exchange proposes to reflect a change to the investment
objective and the means that the Adviser will utilize to implement the
Fund's investment objective. The Prior Release stated that the Fund's
investment objective is to provide long-term total return by investing
long and short in a variety of asset classes and investment strategies.
The Adviser intends to revise the investment objective in the Prior
Release to state that the Fund's investment objective will be to
provide long-term total return and income with a secondary emphasis on
capital preservation. The Prior Release further stated that the Fund,
as part of its principal investments, will invest in exchange-traded
funds (``ETFs'') and other exchange-traded

products, as well as U.S. treasuries, stock index futures, single stock
futures, fixed income futures, currencies and currency futures.
---------------------------------------------------------------------------

    \6\ The term ``under normal market conditions'' as used herein
includes, but is not limited to, the absence of adverse market,
economic, political or other conditions, including extreme
volatility or trading halts in the securities markets or the
financial markets generally; operational issues causing
dissemination of inaccurate market information; or force majeure
type events such as systems failure, natural or man-made disaster,
act of God, armed conflict, act of terrorism, riot or labor
disruption or any similar intervening circumstance. On a temporary
basis, including for defensive purposes, during the initial invest-
up period and during periods of high cash inflows or outflows, the
Fund may depart from its principal investment strategies; for
example, it may hold a higher than normal proportion of its assets
in cash. During such periods, the Fund may not be able to achieve
its investment objective. The Fund may adopt a defensive strategy
when the Adviser and/or the Sub-Adviser believes securities in which
the Fund normally invests have elevated risks due to political or
economic factors and in other extraordinary circumstances.
---------------------------------------------------------------------------

    The Adviser proposes to revise the representations as stated in the
Prior Release to now state that the Fund, as part of its principal
investments, will invest in exchange-traded funds and other exchange-
traded products including but not limited to, exchange-traded notes
(``ETNs''), and closed-end funds (together with ETFs, ``ETPs''). The
Adviser also proposes to revise the representations in the Prior
Release and state that the Fund may now only invest in U.S. treasuries,
stock index futures, single stock futures, fixed income futures,
currencies, and currency futures as ``other investments,'' up to a
maximum of 20% of the Fund's net assets, and no longer as part of the
principal investment strategy.
2. Statutory Basis
    Nasdaq believes that the proposal is consistent with Section 6(b)
of the Act, in general, and Section 6(b)(5) of the Act, in particular,
in that it is designed to prevent fraudulent and manipulative acts and
practices, to promote just and equitable principles of trade, to foster
cooperation and coordination with persons engaged in facilitating
transactions in securities, and to remove impediments to and perfect
the mechanism of a free and open market and in general, to protect
investors and the public interest. The Fund will continue to comply
with all the initial and continued listing requirements under Nasdaq
Rule 5735.
    The Exchange proposes that the Fund be permitted to amend its
investment objective to state that the Fund will invest in ETPs, which
will better-define the objective of the Fund. The Adviser represents
that U.S. treasuries, stock index futures, single stock futures, fixed
income futures, currencies, and currency futures will no longer be part
of the principal investment strategy, and will only be permitted as
``other investments,'' up to a maximum of 20% of the Fund's net assets.
Except for the changes noted above, all other representations made in
the Prior Release remain unchanged.
    For the above reasons, Nasdaq believes the proposed rule change is
consistent with the requirements of Section 6(b)(5) of the Act.

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition that is not necessary or appropriate
in furtherance of the purposes of the Act. The Exchange believes the
proposed rule change will accommodate continued listing and trading of
Managed Fund Shares and will permit the Adviser additional flexibility
in achieving the Fund's investment objectives.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants or Others

    Written comments were neither solicited nor received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Because the foregoing proposed rule change does not: (i)
Significantly affect the protection of investors or the public
interest; (ii) impose any significant burden on competition; and (iii)
become operative for 30 days from the date on which it was filed, or
such shorter time as the Commission may designate, it has become
effective pursuant to Section 19(b)(3)(A)(iii) of the Act \7\ and
subparagraph (f)(6) of Rule 19b-4 thereunder.\8\
---------------------------------------------------------------------------

    \7\ 15 U.S.C. 78s(b)(3)(a)(iii).
    \8\ 17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6)
requires a self-regulatory organization to give the Commission
written notice of its intent to file the proposed rule change at
least five business days prior to the date of filing of the proposed
rule change, or such shorter time as designated by the Commission.
The Exchange has satisfied this requirement.
---------------------------------------------------------------------------

    At any time within 60 days of the filing of the proposed rule
change, the Commission summarily may temporarily suspend such rule
change if it appears to the Commission that such action is: (i)
Necessary or appropriate in the public interest; (ii) for the
protection of investors; or (iii) otherwise in furtherance of the
purposes of the Act. If the Commission takes such action, the
Commission shall institute proceedings to determine whether the
proposed rule should be approved or disapproved.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an email to<EMAIL_ADDRESS>Please include
File Number SR-NASDAQ-2016-082 on the subject line.

Paper Comments

     Send paper comments in triplicate to Secretary, Securities
and Exchange Commission, 100 F Street NE., Washington, DC 20549-1090.

All submissions should refer to File Number SR-NASDAQ-2016-082. This
file number should be included on the subject line if email is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml). Copies of the submission, all subsequent amendments, all
written statements with respect to the proposed rule change that are
filed with the Commission, and all written communications relating to
the proposed rule change between the Commission and any person, other
than those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for Web site viewing and
printing in the Commission's Public Reference Room, 100 F Street NE.,
Washington, DC 20549, on official business days between the hours of
10:00 a.m. and 3:00 p.m. Copies of the filing also will be available
for inspection and copying at the principal office of the Exchange. All
comments received will be posted without change; the Commission does
not edit personal identifying information from submissions. You should
submit only information that you wish to make available publicly. All
submissions should refer to File Number SR-NASDAQ-2016-082 and should
be submitted on or before July 26, 2016.
---------------------------------------------------------------------------

    \9\ 17 CFR 200.30-3(a)(12).

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\9\
Robert W. Errett,
Deputy Secretary.
[FR Doc. 2016-15761 Filed 7-1-16; 8:45 am]
 BILLING CODE 8011-01-P